ReviewFrontiers in nutrition2026
Nutritional bioactives for preventing recurrent urinary tract infections in children: microbiome-mediated mechanisms and clinical implications.
Review in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent urinary tract infections in children represent a common clinical challenge associated with repeated antibiotic exposure and rising antimicrobial resistance. These limitations have intensified interest in non-antibiotic preventive strategies, particularly nutritional bioactives capable of modulating host-microbe interactions. This review provides a clinically oriented synthesis of current evidence on dietary and nutraceutical interventions for the prevention of recurrent pediatric urinary tract infections. Particular attention is given to the limited availability of high-quality pediatric-specific evidence and the heterogeneity of current clinical data. It focuses on cranberry-derived type A proanthocyanidins, probiotics, selected micronutrients and D-mannose. Key mechanistic pathways are also highlighted, including inhibition of uropathogen adhesion, microbiome-mediated biotransformation of bioactives into anti-inflammatory metabolites, and modulation of host immune and epithelial responses within the gut-bladder axis. Available evidence suggests that cranberry products standardized to deliver approximately 36 mg/day of type A proanthocyanidins may reduce recurrence risk, whereas probiotics and vitamins A, C, and D may provide adjunctive benefits through microbiome modulation and enhancement of innate immune responses. However, substantial heterogeneity in study design, variability in formulations and dosing, and the limited availability of high-quality pediatric randomized trials remain important limitations. Building on current evidence, we propose a pragmatic multimodal framework for non-antibiotic prevention in children that integrates nutritional strategies with clinical risk stratification and individualized care, with particular attention to bioavailability, dose standardization and pediatric-specific factors such as age-related microbiome maturation. Future research should prioritize biomarker-driven endpoints, microbiome-informed stratification and adequately powered pediatric studies to define responders and optimize personalized prevention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.